Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 308 entries
View as:

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

Phase: N/A Priority: Normal
NCT ID: NCT01618708 Org: User:
Start: 09/30/12 End: 06/30/15 Due: 06/30/16

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00531232 Org: User:
Start: 05/07/07 End: 05/12/11 Due: 05/12/12

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00047840 Org: User:
Start: 10/31/02 End: 09/30/06 Due: 09/30/07

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Phase: N/A Priority: Normal
NCT ID: NCT00144768 Org: User:
Start: 07/31/04 End: 05/31/07 Due: 05/31/08

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Phase: N/A Priority: Normal
NCT ID: NCT03549871 Org: User:
Start: 07/25/18 End: 03/25/22 Due: 03/25/23

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00004025 Org: User:
Start: 03/31/99 End: - Due: -

Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients

Phase: N/A Priority: Normal
NCT ID: NCT00267514 Org: User:
Start: 01/31/06 End: 05/31/07 Due: 05/31/08

Late-Onset Treatment Study Extension Protocol

Phase: N/A Priority: Normal
NCT ID: NCT00455195 Org: User:
Start: 03/31/07 End: 11/30/08 Due: 11/30/09

Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)

Phase: N/A Priority: Normal
NCT ID: NCT00862836 Org: User:
Start: 04/30/09 End: 09/30/10 Due: 09/30/11

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

Phase: N/A Priority: Normal
NCT ID: NCT00837824 Org: User:
Start: 12/31/02 End: 08/31/03 Due: 08/31/04

Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease

Phase: N/A Priority: Normal
NCT ID: NCT00258011 Org: User:
Start: 12/31/05 End: 10/31/06 Due: 10/31/07

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

Phase: N/A Priority: Normal
NCT ID: NCT00125879 Org: User:
Start: 06/30/05 End: 12/31/06 Due: 12/31/07

Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease

Phase: N/A Priority: Normal
NCT ID: NCT00364858 Org: User:
Start: 12/31/01 End: 02/28/07 Due: 02/28/08

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00113048 Org: User:
Start: 12/31/03 End: 09/30/05 Due: 09/30/06

Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

Phase: N/A Priority: Normal
NCT ID: NCT00410566 Org: User:
Start: 12/31/06 End: 04/30/09 Due: 04/30/10

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Phase: N/A Priority: Normal
NCT ID: NCT00123461 Org: User:
Start: 07/31/05 End: 10/31/07 Due: 10/31/08

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00694590 Org: User:
Start: 06/30/08 End: 09/30/11 Due: 09/30/12

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Phase: N/A Priority: Normal
NCT ID: NCT00507091 Org: User:
Start: 08/31/05 End: 06/30/08 Due: 06/30/09

Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00836043 Org: User:
Start: 10/31/08 End: 04/30/09 Due: 04/30/10

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00146770 Org: User:
Start: 05/31/01 End: 03/31/05 Due: 03/31/06

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

Phase: N/A Priority: Normal
NCT ID: NCT00912925 Org: User:
Start: 12/31/00 End: 09/30/01 Due: 09/30/02

High Dose or High Dose Frequency Study of Alglucosidase Alfa

Phase: N/A Priority: Normal
NCT ID: NCT00483379 Org: User:
Start: 05/31/07 End: 07/31/10 Due: 07/31/11

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT00196716 Org: User:
Start: 06/30/03 End: 03/31/07 Due: 03/31/08

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Phase: N/A Priority: Normal
NCT ID: NCT01650779 Org: User:
Start: 04/30/12 End: 03/31/13 Due: 03/31/14

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00328198 Org: User:
Start: 05/31/06 End: 08/31/11 Due: 08/31/12